These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318 [TBL] [Abstract][Full Text] [Related]
3. Lipoproteins: what, when, and how often to measure. Brown WV Heart Dis Stroke; 1992; 1(1):20-6. PubMed ID: 1344644 [No Abstract] [Full Text] [Related]
12. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kronenberg F; Lingenhel A; Lhotta K; Rantner B; Kronenberg MF; König P; Thiery J; Koch M; von Eckardstein A; Dieplinger H Kidney Int; 2004 Jul; 66(1):348-54. PubMed ID: 15200443 [TBL] [Abstract][Full Text] [Related]
13. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. Nozue T; Michishita I; Mizuguchi I J Atheroscler Thromb; 2010 Feb; 17(1):37-44. PubMed ID: 20075599 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). Afshar M; Pilote L; Dufresne L; Engert JC; Thanassoulis G J Am Heart Assoc; 2016 Apr; 5(4):. PubMed ID: 27108248 [TBL] [Abstract][Full Text] [Related]
15. [Lipoprotein (a) in children with chronic renal failure treated conservatively]. Zwolińska D; Kiliś-Pstrusińska K; Szprynger K Pol Merkur Lekarski; 1997 Sep; 3(15):126-8. PubMed ID: 9461709 [TBL] [Abstract][Full Text] [Related]
16. The effect of reduction of lipoprotein (a) on cellular cholesterol synthesis in non-diabetic and type 2 diabetic subjects. Gilligan S; Owens D; Stinson J; Collins P; Johnson A; Tomkin GH Biochim Biophys Acta; 1995 Jan; 1254(2):187-92. PubMed ID: 7827123 [TBL] [Abstract][Full Text] [Related]
17. [Overview: Atherogenic lipoproteins and their clinical significance]. Shirai K Nihon Rinsho; 2004 Dec; 62 Suppl 12():5-9. PubMed ID: 15658249 [No Abstract] [Full Text] [Related]
18. The Gordon Wilson Lecture. Plasma cholesterol: atherogenesis and mortality. Fisher WR Trans Am Clin Climatol Assoc; 1993; 104():77-92; discussion 92-3. PubMed ID: 1343450 [No Abstract] [Full Text] [Related]
19. [Treatment of hyperlipidemia in diabetes mellitus]. Onuma T; Kawamori R Nihon Rinsho; 2001 Mar; 59 Suppl 3():143-51. PubMed ID: 11347047 [No Abstract] [Full Text] [Related]
20. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). Svensson J; Jansson JO; Ottosson M; Johannsson G; Taskinen MR; Wiklund O; Bengtsson BA J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]